31
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Editorial: Perinatal mood symptoms and postpartum maternal functioning: Describing the evidence related to effective and ineffective interventions

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The goal of this special issue entitled, “Perinatal mood symptoms and postpartum maternal functioning: Describing the evidence related to effective and ineffective interventions,” was to highlight interventions that have been evaluated in peer-reviewed research in regards to their efficacy toward improving perinatal mood symptoms and/or postpartum maternal functioning. While there is a comparatively rich body of research surrounding perinatal depression and anxiety, postpartum maternal functioning has exacted less attention, to date (1–3). There are several reasons for this including: (1) an early and almost exclusive focus on postpartum depression (PPD) as the primary mental health concern of interest in new mothers (4), (2) a lack of current, quick, and accurate tools to assess postpartum functional status (2), (3) inadequate attention paid to mothers and their needs post childbirth (5, 6), and a predominant focus on infant health and the clinical outcomes of the pregnancy (5). However, over the past 10 years, assessment of maternal functioning has made its way into the conversation, and also into domestic (7–10), international (11–13), and industry-sponsored studies (14, 15). Though the evidence base is still growing, we do know that some interventions seem to improve maternal functioning. For example, women who participated in the Visiting Moms® program in Waltham, Massachusetts (n = 149), scored, on average, 16 points higher on the Barkin Index of Maternal Functioning (BIMF) (1) at program completion (relative to program intake) (4). This intervention included weekly home visits from trained volunteers through the baby's first year of life and corroborates the knowledge base indicating that social support is a protective factor (4). Postpartum patient education via the Skills Training Approach (STA) also appeared efficacious at improving maternal functioning—across all domains—in a small randomized controlled (n = 68) trial of Iranian women (11). In fact, the group of women who received maternal skills training shortly after childbirth had an average BIMF score of 95.8 vs. 70.3 in the control group (11). Stated differently, the women who received postpartum education were functioning, on average, 25 points higher than those who received usual care, making the case for more education-centered approaches to functional improvement. Clinical interventions such as the Hennepin Healthcare Mother-Baby Day Hospital, where perinatal women with severe to moderate psychiatric illness receive trauma-informed group-based therapy and psychiatric care, have shown great promise and significant improvements in depression, anxiety, and maternal functioning (16). Intensive Outpatient Programs (I.O.P.s) have likewise reported success in achieving functional improvement in postpartum women (17). Through this special issue, both promising interventions and risk/protective factors associated with perinatal mental health are explored. For example, Deif et al. examine the complex role of breastfeeding in relation to maternal mood (18), via a literature review focused on Dysphoric Milk Ejection Reflex (D-MER). Likewise, Iodice et al. consider the role of Oxytocin, concluding that the hormone may play a protective role in the development of perinatal depression. In a hygiene-focused study, Jiang et al. explored the association between caregiver hand washing practice and postpartum mental health; results from this cross-sectional study implicate suboptimal hand washing practice as a risk factor for maternal depression, anxiety, and stress. In terms of new behavioral health interventions, Flynn et al., Monteiro et al., and Peifer et al. each report compelling results and innovative programming. The special issue is nicely rounded out with an opinion piece by Albanese et al. who call for more patient-centered research and interventions for new mothers, whose mental health needs have been historically minimized (9). While we continue to think about ways to support pregnant and postpartum women toward holistic mental health and optimal daily functioning, there is a looming threat (risk factor) on the horizon and its name is the climate crisis (5). In fact, the World Bank recently issued a report estimating that more then 200 million people are likely to be displaced due to climate change/extreme weather events (EWEs) over the next 30 years (19). We also know that women and children are vulnerable subgroups and are disproportionately affected (20). As the climate crisis intensifies, more pregnant and postpartum women will be impacted economically, socially, mentally, and physically. Organizations that assist new mothers, such as Postpartum Support International (PSI) (21), should strongly consider incorporation of climate change effects into their programming. Healthcare providers serving the perinatal population will need to consider environmental factors, including extreme heat, when assessing their patients' mental (and physical) wellness. Author contributions The author confirms being the sole contributor of this work and has approved it for publication. Conflict of interest The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial

          Post-partum depression is a serious mood disorder in women that might be triggered by peripartum fluctuations in reproductive hormones. This phase 2 study investigated brexanolone (USAN; formerly SAGE-547 injection), an intravenous formulation of allopregnanolone, a positive allosteric modulator of γ-aminobutyric acid (GABAA) receptors, for the treatment of post-partum depression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Effect of Zuranolone vs Placebo in Postpartum Depression : A Randomized Clinical Trial

            This randomized clinical trial assesses the efficacy and safety of zuranolone, a neuroactive steroid γ-aminobutyric acid receptor–positive allosteric modulator, in individuals with postpartum depression. Question Does treatment with zuranolone reduce depressive symptoms in female individuals experiencing postpartum depression? Findings In this phase 3, double-blind, randomized, placebo-controlled trial of 151 adult women with postpartum depression, patients taking daily zuranolone for 2 weeks displayed greater statistically significant reductions in depressive symptoms compared with placebo at day 15, assessed by change from baseline in the 17-item Hamilton Rating Scale for Depression. Reductions in depressive symptoms were observed by day 3 and sustained at all measured time points through day 45. Meaning Zuranolone provided significant reductions in depressive symptoms and was generally well tolerated, supporting its further development in the treatment of postpartum depression. Importance Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy, negatively affecting both mother and child. Objective To demonstrate the efficacy and safety of zuranolone, a neuroactive steroid γ-aminobutyric acid receptor–positive allosteric modulator, in PPD. Design, Setting, and Participants This phase 3, double-blind, randomized, outpatient, placebo-controlled clinical trial was conducted between January 2017 and December 2018 in 27 enrolling US sites. Participant were women aged 18 to 45 years, 6 months or fewer post partum, with PPD (major depressive episode beginning third trimester or ≤4 weeks postdelivery), and baseline 17-item Hamilton Rating Scale for Depression (HAMD-17) score of 26 or higher. Analysis was intention to treat and began December 2018 and ended March 2019. Interventions Randomization 1:1 to placebo:zuranolone, 30 mg, administered orally each evening for 2 weeks. Main Outcomes and Measures Primary end point was change from baseline in HAMD-17 score for zuranolone vs placebo at day 15. Secondary end points included changes from baseline in HAMD-17 total score at other time points, HAMD-17 response (≥50% score reduction) and remission (score ≤7) rates, Montgomery-Åsberg Depression Rating Scale score, and Hamilton Rating Scale for Anxiety score. Safety was assessed by adverse events and clinical assessments. Results Of 153 randomized patients, the efficacy set comprised 150 patients (mean [SD] age, 28.3 [5.4] years), and 148 (98.7%) completed treatment. A total of 76 patients were randomized to placebo, and 77 were randomized to zuranolone, 30 mg. Zuranolone demonstrated significant day 15 HAMD-17 score improvements from baseline vs placebo (−17.8 vs −13.6; difference, −4.2; 95% CI, −6.9 to −1.5; P  = .003). Sustained differences in HAMD-17 scores favoring zuranolone were observed from day 3 (difference, −2.7; 95% CI, −5.1 to −0.3; P  = .03) through day 45 (difference, −4.1; 95% CI, −6.7 to −1.4; P  = .003). Sustained differences at day 15 favoring zuranolone were observed in HAMD-17 response (odds ratio, 2.63; 95% CI, 1.34-5.16; P  = .005), HAMD-17 score remission (odds ratio, 2.53; 95% CI, 1.24-5.17; P  = .01), change from baseline for Montgomery-Åsberg Depression Rating Scale score (difference, −4.6; 95% CI, −8.3 to −0.8; P  = .02), and Hamilton Rating Scale for Anxiety score (difference, −3.9; 95% CI, −6.7 to −1.1; P  = .006). One patient per group experienced a serious adverse event (confusional state in the zuranolone group and pancreatitis in the placebo group). One patient in the zuranolone group discontinued because of an adverse event vs none for placebo. Conclusions and Relevance In this randomized clinical trial, zuranolone improved the core symptoms of depression as measured by HAMD-17 scores in women with PPD and was generally well tolerated, supporting further development of zuranolone in the treatment of PPD. Trial Registration ClinicalTrials.gov Identifier: NCT02978326
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Development of the Barkin Index of Maternal Functioning.

              Maternal functional status is important to capture in the 12 months after childbirth, as this period marks a critical window for both mother and child. In most cases, mothers are the primary caregivers and are, therefore, responsible for the majority of the work related to infant care tasks, such as feeding, diaper changes, and doctor's appointments. Additionally, the quality of mother-child interaction in the year after childbirth affects child development. To date, postpartum functioning has exacted scarce coverage, with only one instrument claiming to measure the concept explicitly. This necessitated the development of the Barkin Index of Maternal Functioning (BIMF), which was designed to measure functioning in the year after childbirth.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Psychiatry
                Front Psychiatry
                Front. Psychiatry
                Frontiers in Psychiatry
                Frontiers Media S.A.
                1664-0640
                28 July 2022
                2022
                : 13
                : 975078
                Affiliations
                Mercer University School of Medicine , Macon, GA, United States
                Author notes

                Edited and reviewed by: Marcin Siwek, Jagiellonian University, Medical College, Poland

                *Correspondence: Jennifer L. Barkin barkinj@ 123456gmail.com

                This article was submitted to Mood Disorders, a section of the journal Frontiers in Psychiatry

                Article
                10.3389/fpsyt.2022.975078
                9366854
                7a38e2bb-8bb6-4fa6-93a4-7cbe340161df
                Copyright © 2022 Barkin.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 21 June 2022
                : 01 July 2022
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 21, Pages: 0, Words: 1711
                Categories
                Psychiatry
                Editorial

                Clinical Psychology & Psychiatry
                postpartum functioning,perinatal mental health,maternal functioning,barkin index of maternal functioning,climate anxiety

                Comments

                Comment on this article